Antares Pharma, Inc. has announced the approval of Xyosted (testosterone enanthate) injection by the US Food and Drug Administration (FDA) for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Xyosted is the first FDA-approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. Antares Pharma, Inc., is headquartered in Ewing, NJ.
Dosage/administration: Xyosted has been approved in 3 dosage strengths, 50 mg, 75 mg, and 100 mg.
Adverse reactions: The most commonly reported adverse reactions (>5%) were increased hematocrit, hypertension, increased PSA, injection site bruising, and headache.
Antares receives FDA approval of Xyosted (testosterone enanthate) injection for testosterone replacement therapy in adult males. [news release]. Ewing, NJ: Antares Pharma, Inc. October 1, 2018. https://www.antarespharma.com/application/files/2715/3835/7488/XYOSTED_FDA_Approval_Final.pdf. Accessed October 3, 2018.
This Week's Must Reads
Must Reads in FDA Actions
FDA Approves Xyosted for Testosterone Replacement, Antares Pharma news release; 2018 Oct 1
FDA Approves Implantable Glucose Sensor Device, FDA Web site; 2018 Jun 21
FDA Approves Updates to Tresiba Label, Novo Nordisk news release; 2018 Mar 26
FDA Approves Integrated Continuous GM System, FDA Web site; 2018 Mar 27
FDA Approves New Guardian Sensor 3 Arm Indication , Medtronic news release; 2018 Feb 26